Illumina Historical Income Statement
ILMN Stock | USD 136.99 5.31 4.03% |
Historical analysis of Illumina income statement accounts such as Total Revenue of 4.7 B or Gross Profit of 2.9 B can show how well Illumina performed in making a profits. Evaluating Illumina income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Illumina's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Illumina latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Illumina is a good buy for the upcoming year.
Illumina |
About Illumina Income Statement Analysis
Illumina Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Illumina shareholders. The income statement also shows Illumina investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Illumina Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Illumina generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Illumina minus its cost of goods sold. It is profit before Illumina operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Most accounts from Illumina's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Illumina current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.At this time, Illumina's Total Operating Expenses is very stable compared to the past year. As of the 21st of November 2024, Income Tax Expense is likely to grow to about 75 M, while Interest Expense is likely to drop about 60.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 3.2B | 3.0B | 2.7B | 2.9B | Total Revenue | 4.5B | 4.6B | 4.5B | 4.7B |
Illumina income statement Correlations
Click cells to compare fundamentals
Illumina Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Illumina income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 188M | 187M | 251M | 394M | 432M | 453.6M | |
Interest Expense | 52M | 49M | 61M | 26M | 77M | 60.3M | |
Total Revenue | 3.5B | 3.2B | 4.5B | 4.6B | 4.5B | 4.7B | |
Gross Profit | 2.5B | 2.2B | 3.2B | 3.0B | 2.7B | 2.9B | |
Other Operating Expenses | 2.6B | 2.7B | 4.6B | 4.2B | 4.7B | 5.0B | |
Operating Income | 985M | 393M | (123M) | (4.2B) | (1.1B) | (1.0B) | |
Ebit | 985M | 393M | (123M) | (4.2B) | (1.1B) | (1.0B) | |
Research Development | 647M | 682M | 1.2B | 1.3B | 1.4B | 1.4B | |
Ebitda | 1.2B | 580M | 128M | (3.8B) | (1.1B) | (1.0B) | |
Cost Of Revenue | 1.1B | 1.0B | 1.4B | 1.6B | 1.8B | 1.8B | |
Total Operating Expenses | 1.5B | 1.6B | 3.3B | 7.2B | 3.0B | 3.1B | |
Net Income | 1.0B | 656M | 762M | (4.4B) | (1.2B) | (1.1B) | |
Income Tax Expense | 128M | 200M | 122M | 68M | 44M | 75.0M | |
Selling General Administrative | 835M | 941M | 2.1B | 1.3B | 1.6B | 1.7B | |
Income Before Tax | 1.1B | 856M | 884M | (4.3B) | (1.1B) | (1.1B) | |
Total Other Income Expense Net | 133M | 463M | 1.0B | (8.8B) | (48M) | (50.4M) | |
Net Income Applicable To Common Shares | 1.0B | 656M | 762M | (4.4B) | (4.0B) | (3.8B) | |
Net Income From Continuing Ops | 990M | 656M | 762M | (4.4B) | (1.2B) | (1.1B) | |
Non Operating Income Net Other | 185M | 325M | 1.1B | (157M) | (180.6M) | (171.5M) | |
Tax Provision | 128M | 200M | 122M | 68M | 44M | 41.8M | |
Interest Income | 75M | 41M | 919M | 11M | 58M | 55.1M | |
Net Interest Income | 23M | (8M) | (61M) | (15M) | (19M) | (20.0M) | |
Reconciled Depreciation | 188M | 187M | 251M | 394M | 432M | 280.8M |
Pair Trading with Illumina
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Illumina position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Illumina will appreciate offsetting losses from the drop in the long position's value.Moving against Illumina Stock
0.69 | VCNX | Vaccinex | PairCorr |
0.58 | DTIL | Precision BioSciences | PairCorr |
0.53 | VALN | Valneva SE ADR Downward Rally | PairCorr |
0.52 | ME | 23Andme Holding | PairCorr |
0.51 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to Illumina could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Illumina when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Illumina - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Illumina to buy it.
The correlation of Illumina is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Illumina moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Illumina moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Illumina can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Illumina. If investors know Illumina will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Illumina listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share (9.98) | Revenue Per Share 27.654 | Quarterly Revenue Growth (0.04) | Return On Assets 0.0262 |
The market value of Illumina is measured differently than its book value, which is the value of Illumina that is recorded on the company's balance sheet. Investors also form their own opinion of Illumina's value that differs from its market value or its book value, called intrinsic value, which is Illumina's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Illumina's market value can be influenced by many factors that don't directly affect Illumina's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Illumina's value and its price as these two are different measures arrived at by different means. Investors typically determine if Illumina is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Illumina's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.